Cantor Fitzgerald Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $7
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $1.5
X4 Pharmaceuticals Price Target Maintained With a $3.00/Share by Cantor Fitzgerald
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $3 Price Target
Analysts Are Bullish on Top Healthcare Stocks: X4 Pharmaceuticals (XFOR), Sanara MedTech (SMTI)
X4 Pharmaceuticals Analyst Ratings
Piper Sandler Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $2
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), X4 Pharmaceuticals (XFOR) and IQVIA Holdings (IQV)
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $1.5
Strategic Restructuring and Market Opportunities Drive Buy Rating for X4 Pharmaceuticals
Piper Sandler Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $2
X4 Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $1.5
Stifel Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (TVTX), Treace Medical Concepts (TMCI) and X4 Pharmaceuticals (XFOR)